Creabilis appoints new chief executive

Eliot Forster brings significant drug development experience to firm

Creabilis, a clinical stage European biotechnology company addressing significant unmet medical needs in dermatological diseases, has appointed Eliot Forster as its new chief executive.

Forster brings almost 20 years’ industry experience in biotechnology and pharmaceutical companies to the Luxembourg-based firm.

He was most recently chief executive of Solace Pharmaceuticals, a US-based biotech. Prior to this, was Pfizer’s head of EU development and of development operations in the EU and Asia. During his career at Pfizer Forster was integral to bringing a number of drugs to market, including Celebrex (celecoxib), Bextra (valcecoxib) and Relpax (eletriptan).

Creabilis’ lead product is CT327, a novel topically applied TrkA kinase inhibitor developed using the Company’s LSE (Low Systemic Exposure) technology. It is currently in Phase II clinical trials in psoriasis and atopic dermatitis.

The Creabilis portfolio also includes CT637, a new approach to the treatment of significant inflammatory conditions such as rheumatoid arthritis as well as severe psoriasis.

You may also like

Finance

Creabilis establishes UK operation

Location in Kent broadens the county’s links with the pharma industry
Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates
Design & Build

Entries closed: what’s next for the Cleanroom Technology Awards?

With entries now closed, attention turns to the next phase of the awards programme
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities

The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258

The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
Drug Delivery

Palvella's QTORIN achieves positive Phase III results

Working in collaboration with MedPharm, the biopharma company announced positive topline results from its Phase 3 SELVA study of QTORIN rapamycin, paving the way for the company to prepare for commercial-scale manufacturing
Drug Delivery

New cancer drug delivery system boosts absorption of Paclitaxel

Researchers from Osaka Metropolitan University have developed a drug-delivery system that effectively delivers anticancer medication to cancerous tissues, potentially offering a solution for therapeutics that are difficult to absorb
Subscribe now